Scientists Identify Hidden Brain Pathway Behind GLP

A new study shows oral GLP-1 drugs suppress hedonic eating through a deep- brain reward circuit linked to dopamine release, potentially extending their use beyond weight loss .

A new study shows oral GLP-1 drugs suppress hedonic eating through a deep- brain reward circuit linked to dopamine release, potentially extending their use beyond weight loss . Why do GLP-1 weight-loss drugs seem to quiet cravings in ways that go beyond simple appetite suppression?
NIH researchers identify avenue for enhanced GLP

The weight-loss benefits of GLP-1s are well documented and scientists generally know the brain regions associated with these effects . However, several questions remain, such as why responses to medication differ between patients and why the effects for most eventually plateau.
The findings offer a deeper look into the brain chemistry behind GLP-1 medications and may help guide the development of more effective weight loss treatments in the future.

The GLP
GLP‑1 weight‑loss drugs like semaglutide and tirzepatide are redefining how scientists and the public understand obesity, appetite and metabolic disease. At the University of Alabama at Birmingham, researchers are uncovering how these medications work in the brain .
GLP-1 weight-loss drugs alter brain circuits in the amygdala and dopamine system to reduce the motivation to seek out high-calorie foods.

Mechanisms of GLP
Abstract Glucagon-like peptide-1 ( GLP-1 ) receptor agonists (RAs) have become central in managing obesity and type 2 diabetes, primarily through appetite suppression and metabolic regulation. This review explores the mechanisms underlying GLP-1 RA-induced weight loss , focusing on central and peripheral pathways .
UVA professor Ali Güler (pictured left) and members of his research team, whose Nature study shows that a new class of oral GLP‑1 weight‑loss drugs can act on brain circuits involved in reward and motivation, reshaping not just appetite but the desire for food.

A brain reward circuit inhibited by next
Humanized glucagon-like peptide 1 receptor (GLP1R) mouse models are used to investigate the neural circuitry through which small-molecule GLP1R agonists modulate feeding, with implications for how ...




